AlloVir Inc (ALVR)       3.9  -0.03 (-0.76%)

3.9  -0.03 (-0.76%)

US0198181036 - Common Stock - After market: 3.9 0 (0%)

AlloVir Inc3.9

NASDAQ:ALVR (6/30/2022, 7:00:01 PM)-0.03 (-0.76%)

After market: 3.9 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 05-05 2022-05-05/bmo Earnings (Next) 08-04 2022-08-04
Ins Owners 7.52% Inst Owners 42.68%
Market Cap 250.84M Shares 64.32M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 84
IPO 07-30 2020-07-30

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ALVR Daily chart

Company Profile

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The company is headquartered in Waltham, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2020-07-30. The firm is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). VST manufacturing platform enables the reproducible generation of single-virus and multi-virus specific cell therapeutic candidates.

Company Info

AlloVir Inc

1100 Winter Street

Waltham MASSACHUSETTS 02142

P: 16174332605.0

CEO: David Hallal

Employees: 107

Website: https://www.allovir.com

News

News Image24 days ago - AlloVir, Inc.AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant RecipientsNews Imagea month ago - Market News VideoFirst Week of January 2023 Options Trading For AlloVir (ALVR)News Image2 months ago - AlloVir, Inc.AlloVir Reports First Quarter 2022 Financial ResultsNews Image2 months ago - Market News VideoNotable Wednesday Option Activity: ALVR, AMZN, GOOGLNews Image2 months ago - InvestorPlaceWhy Is AlloVir (ALVR) Stock Up 30% Today?

AlloVir (ALVR) stock is taking off on Wednesday following an update from the U.S. Food and Drug Administration (FDA) on posoleucel.

ALVR Twits

Here you can normally see the latest stock twits on ALVR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example